BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

847 related articles for article (PubMed ID: 11330962)

  • 1. Analysis of FIGO Stage IIIc endometrial cancer patients.
    McMeekin DS; Lashbrook D; Gold M; Johnson G; Walker JL; Mannel R
    Gynecol Oncol; 2001 May; 81(2):273-8. PubMed ID: 11330962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nodal distribution and its significance in FIGO stage IIIc endometrial cancer.
    McMeekin DS; Lashbrook D; Gold M; Scribner DR; Kamelle S; Tillmanns TD; Mannel R
    Gynecol Oncol; 2001 Aug; 82(2):375-9. PubMed ID: 11531298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FIGO stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes: analysis of treatment outcomes, prognostic variables, and failure patterns following adjuvant radiation therapy.
    Nelson G; Randall M; Sutton G; Moore D; Hurteau J; Look K
    Gynecol Oncol; 1999 Nov; 75(2):211-4. PubMed ID: 10525373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.
    Watari H; Todo Y; Takeda M; Ebina Y; Yamamoto R; Sakuragi N
    Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FIGO stage IIIC endometrial carcinoma: prognostic factors and outcomes.
    Hoekstra AV; Kim RJ; Small W; Rademaker AW; Helenowski IB; Singh DK; Schink JC; Lurain JR
    Gynecol Oncol; 2009 Aug; 114(2):273-8. PubMed ID: 19428094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Para-aortic lymphadenectomy may improve disease-related survival in patients with multipositive pelvic lymph node stage IIIc endometrial cancer.
    Fujimoto T; Nanjyo H; Nakamura A; Yokoyama Y; Takano T; Shoji T; Nakahara K; Yamada H; Mizunuma H; Yaegashi N; Sugiyama T; Kurachi H; Sato A; Tanaka T
    Gynecol Oncol; 2007 Nov; 107(2):253-9. PubMed ID: 17640720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology.
    Lutman CV; Havrilesky LJ; Cragun JM; Secord AA; Calingaert B; Berchuck A; Clarke-Pearson DL; Soper JT
    Gynecol Oncol; 2006 Jul; 102(1):92-7. PubMed ID: 16406063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation.
    Jolly S; Vargas CE; Kumar T; Weiner SA; Brabbins DS; Chen PY; Floyd W; Martinez AA
    Gynecol Oncol; 2006 Oct; 103(1):87-93. PubMed ID: 16545441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
    Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
    Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference?
    Rutledge TL; Kamelle SA; Tillmanns TD; Gould NS; Wright JD; Cohn DE; Herzog TJ; Rader JS; Gold MA; Johnson GA; Walker JL; Mannel RS; McMeekin DS
    Gynecol Oncol; 2004 Oct; 95(1):70-6. PubMed ID: 15385112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Survival, prognostic factors and modern tendencies in adjuvant treatment of diagnosed endometrial cancer patients with or without lymph node dissection].
    Ivanov I
    Akush Ginekol (Sofiia); 2009; 48 Suppl 1():3-11. PubMed ID: 20387272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
    Ma SK; Zhang HT; Sun YC; Wu LY
    Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):690-4. PubMed ID: 19173912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer.
    Havrilesky LJ; Cragun JM; Calingaert B; Alvarez Secord A; Valea FA; Clarke-Pearson DL; Berchuck A; Soper JT
    Gynecol Oncol; 2007 Feb; 104(2):401-5. PubMed ID: 17014898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
    Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
    Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Multivariate analysis of prognostic factors in endometrial carcinoma].
    Li B; Wu LY; Li SM; Zhang WH; Zhang R; Ma SK
    Ai Zheng; 2004 Sep; 23(9):1085-8. PubMed ID: 15363208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
    Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
    Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Modern tendencies in treatment of endometrial cancer stage III C].
    Ivanov SI
    Akush Ginekol (Sofiia); 2008; 47(3):29-31. PubMed ID: 18756829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
    Alektiar KM; Venkatraman E; Chi DS; Barakat RR
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):111-7. PubMed ID: 15850910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of failures in patients with FIGO stage IIIc1-IIIc2 endometrial cancer.
    Gadducci A; Cosio S; Fabrini MG; Guerrieri ME; Greco C; Genazzani AR
    Anticancer Res; 2012 Jan; 32(1):201-5. PubMed ID: 22213308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymph-vascular space involvement and outer one-third myometrial invasion are strong predictors of distant haematogeneous failures in patients with stage I-II endometrioid-type endometrial cancer.
    Gadducci A; Cavazzana A; Cosio S; DI Cristofano C; Tana R; Fanucchi A; Teti G; Cristofani R; Genazzani AR
    Anticancer Res; 2009 May; 29(5):1715-20. PubMed ID: 19443392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.